The Johnson & Johnson company published some data showing that giving a boosting dose of its coronavirus vaccine provides a strong immune response after a few months of taking the first dose.
In a statement Tuesday, J&J said it had conducted two early studies involving people who had received its vaccine. The findings showed that a second dose produced an increased immune response in people aged 18 to 55 years. The results of the studies have not yet been reviewed by other experts in the field.
The company announced that it is in talks with the US Food and Drug Administration, the European Medicines Agency and other agencies regarding the use of booster doses of its vaccine.
The J&J vaccine has been approved for use in the United States, throughout Europe, and plans are that at least 200 million doses will be distributed thanks to the UN-supported COVAX program, which aims to distribute vaccines to poor countries. But the company is facing production problems. Meanwhile she was forced to dump millions of troubled doses produced at a factory in Baltimore.
The J&J vaccine has been considered critical to ending the pandemic by many health officials as it is given in a single dose. The fear associated with the delta variant of the more rapidly spreading coronavirus has prompted various governments to consider using booster injections for many approved vaccines.
Last week, FDA experts recommended that people over the age of 65 receive a third dose of the COfid-19s vaccine produced by Pfizer-BioNTech while Britain had previously authorized booster injections for people over the age of 50. Other countries including Israel, France and Germany have also started offering third doses of vaccines to some groups.
The World Health Organization has called on rich countries to stop boosting doses until at least the end of the year, saying vaccines should be sent immediately to Africa, where less than 4% of the population is fully immunized.
To be part of the group »AOL“just click: Join Group and your request will be approved immediately.